Description: McKesson has outstripped the S&P 500 Index's rally over the past year, igniting analysts’ unflinching optimism about the healthcare stock's steadfast, upward trajectory.

Description: Curious if McKesson is currently a bargain, or if the impressive run has left little value on the table? Let’s explore what is influencing opinions on its price and consider the factors that may shape its outlook. McKesson’s shares have increased recently, climbing 3.7% last week, 8.9% over the past month, and delivering a substantial 56.1% year-to-date return. This reflects both momentum and changes in risk perceptions. Industry discussion has focused on McKesson’s expansion into specialty...

Description: Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Description: McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Specialty Distributor Now Stocked: ORLYNVAH™ is now available at McKesson, which will allow certain physicians the ability to procure the product d

Description: A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Description: McKesson has outpaced the broader market returns over the past year, and analysts remain upbeat on MCK, noting the company’s reliable growth momentum and supportive earnings outlook.

Description: Key Insights Institutions' substantial holdings in McKesson implies that they have significant influence over the...

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Description: Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: As Wall Street rebounds on hopes of a shutdown resolution, investors turn to value picks like LTH, CAH, MCK and FLS with strong interest coverage ratios.

Description: It's been a good week for McKesson Corporation ( NYSE:MCK ) shareholders, because the company has just released its...

Description: McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Description: Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.

Description: McKesson’s fair value estimate has increased slightly, with the price target moving from $836.71 to $844.57. This adjustment comes as analysts respond positively to the company’s improved long-term outlook and strategic initiatives. Read on to discover how you can stay on top of these shifting market narratives in the weeks ahead. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value McKesson. What Wall Street Has Been Saying 🐂...

Description: MD's Q3 profit tops on lower expenses and improved patient acuity, driving earnings past estimates despite softer revenues.

Description: McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.

Description: NEW PROVIDENCE, N.J., November 06, 2025--PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices.

Description: Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering nove

Description: McKesson Corp (MCK) reports a 10% revenue increase and raises earnings guidance, despite challenges in the medical surgical solutions segment.

Description: While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: McKesson (MCK) delivered earnings and revenue surprises of +10.54% and -1.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Healthcare distributor and services company McKesson (NYSE:MCK) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 10.1% year on year to $103.2 billion. Its non-GAAP profit of $9.86 per share was 8.9% above analysts’ consensus estimates.

Description: IRVING, Texas (AP) — McKesson Corp. MCK) on Wednesday reported fiscal second-quarter earnings of $1.11 billion. On a per-share basis, the Irving, Texas-based company said it had profit of $8.92.

Description: IRVING, Texas, November 05, 2025--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 second quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

Description: Lifevantage (LFVN) delivered earnings and revenue surprises of +5.88% and -10.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Alkira®, the leader in Network Infrastructure as a Service (NIaaS), today announced the appointment of Maria N. Martinez to its advisory board.

Description: Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.

Description: McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.

Description: Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting earnings this Wednesday afternoon. Here’s what investors should know.

Description: In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for certain cutaneous T-cell lymphoma patients, with national distribution ahead of its planned commercial launch later in the year. This collaboration completes LYMPHIR’s U.S. distribution network through the nation’s three largest pharmaceutical wholesalers, highlighting McKesson’s central role in...

Description: Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...

Description: Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

Description: Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Description: Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: IRVING, Texas, October 30, 2025--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on January 2, 2026 to shareholders of record on December 1, 2025.

Description: Cardinal (CAH) delivered earnings and revenue surprises of +15.38% and +8.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Key Insights McKesson's estimated fair value is US$1,366 based on 2 Stage Free Cash Flow to Equity Current share price...

Description: McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: McKesson (MCK) is trading at new all-time highs and has strong technical momentum. MCK has a 100% “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Analyst sentiment is overwhelmingly positive, with multiple “Strong Buy” ratings and price targets up to $984, despite some valuation concerns....

Description: Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc.(Nasdaq:VSEE) (the "Company"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). ...

Description: The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California

Description: McKesson (MCK) has delivered share price gains month after month, with its stock rising 5% in the past month and an impressive 13% over the past 3 months. The company’s performance raises questions about whether this growth momentum can be sustained. See our latest analysis for McKesson. Momentum has truly been building for McKesson, with its share price climbing over 41% year to date and its total shareholder return for the past year reaching nearly 59%. While there have been no major...

Description: McKesson (MCK) reached $801.67 at the closing of the latest trading day, reflecting a +1.1% change compared to its last close.

Description: Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: While the S&P 500 is up 22.9% since April 2025, McKesson (currently trading at $792.23 per share) has lagged behind, posting a return of 15.1%. This may have investors wondering how to approach the situation.

Description: McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.

Description: The Fair Value Estimate for McKesson stock has risen slightly to $836.71 from $829.57, following a series of updates after the company’s recent investor day. This modest increase reflects renewed optimism stemming from updated financial guidance and the company’s focus on high-growth and higher-margin business areas. Stay tuned to see how investors and analysts are interpreting these narrative shifts to keep up with McKesson’s evolving story. What Wall Street Has Been Saying Analyst reactions...

Description: McKesson is expected to announce its second-quarter results next month, and analysts predict a double-digit increase in the company’s bottom-line figure.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Description: Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth

Description: Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...

Description: McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.

Description: West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.